Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Increases Alza Ante By $5 Bil. Over Abbott: Concerta Has J&J Upbeat

Executive Summary

Johnson & Johnson is offering about 67% ($5 bil.) more than Abbott did in 1999 to bring Alza's $700 mil. annual sales product line and its extended-release product development skills into the J&J family.
Advertisement

Related Content

J&J Acquires Crystalline Technology Through $230 Mil. TransForm Buy
J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
Pharma/Biotech Deals: Are Today’s Collaborations Tomorrow’s Acquisitions?
Pharma/Biotech Deals: Are Today’s Collaborations Tomorrow’s Acquisitions?
J&J Adds New Dimension To Drug Discovery Efforts With 3DP Acquisition
Cellegy management expansion
J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems
J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems
Federal Rx Budgets Are Argument Against Patent Extensions - Schumer
Advertisement
UsernamePublicRestriction

Register

PS037591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel